# A Review of ARID1A’s Role in Breast Cancer Progression: Context-Dependent Mechanisms and Therapeutic Implications

## TL;DR

This paper reviews how ARID1A, a protein involved in DNA regulation, can both suppress and promote breast cancer depending on the context, suggesting it could be a useful target for treatment.

## Contribution

The paper highlights ARID1A's dual, context-dependent role in breast cancer progression, offering new insights into its potential as a biomarker and therapeutic target.

## Key findings

- ARID1A loss disrupts DNA repair and promotes aggressive tumor growth through EMT and PI3K/AKT signaling.
- Abnormal ARID1A overexpression can induce oxidative stress and potentially initiate tumor growth.
- ARID1A's context-dependent function suggests its potential as a diagnostic biomarker and therapeutic target.

## Abstract

Around 2.3 million new breast cancer cases arise every year globally. Early diagnosis and targeted therapy are important to developing new therapeutic drugs for breast cancer treatment. This study aims to understand the context-dependent role of ARID1A, a key component of the SWI/SNF chromatin remodeling complex that shows frequent alterations across cancers, including breast cancer. Understanding ARID1A’s role is important because loss of ARID1A disrupts DNA repair, cell-cycle control, and chromatin regulation, leading to aggressive tumor progression via enhancing EMT and activating PI3K/AKT oncogenic signaling; conversely, abnormal overexpression of ARID1A may induce oxidative stress by CYP450 and initiate tumor growth. Thus, this study highlights the context-dependent role of ARID1A and supports its potential as a diagnostic biomarker and therapeutic target for the treatment management of breast cancer and other malignancies.

ARID1A, a key subunit of the SWI/SNF chromatin remodeling complex, plays a context-dependent function in cancer, acting both as a tumor suppressor and, in certain conditions, as an oncogene. ARID1A, as a tumor suppressor, maintains transcriptional regulation, genomic stability, and cellular differentiation. In breast cancer, ARID1A loss-of-function leads to dysregulation of cell cycle checkpoints and impaired DNA repair and promotes epithelial-to-mesenchymal transition (EMT), jointly accelerating tumor proliferation and increasing therapeutic resistance. Notably, context-dependent ARID1A loss-of-function often concurs with activation of the PI3K/AKT signaling pathway and corresponds with poor prognosis. On the contrary, aberrant ARID1A overexpression can provoke oxidative stress and agitate the cytochrome P450 system, potentially facilitating early tumorigenesis. Consequently, understanding ARID1A’s dual and context-dependent role highlights its potential as a biomarker and therapeutic target in precision oncology.